Novel approaches to Behçet’s disease

Bibliography

• SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. N Engl. J. Med. (1999) 341 (17) :1284–1291.
   PubMed Web of Science ®Google Scholar
• •This is an authoritative review covering basic and clinical aspects of Behçet's disease.
   Google Scholar
• KASTNER DL: Intermittent and periodic arthritic syndromes. In: Arthritis and Allied Conditions: a Textbook of Rheumatology (13th Ed.). Koopman WJ (Ed.), Williams & Wilkins, Baltimore, USA (1997):1279–1306.
   Google Scholar
• KAKLAMANI VG, VAIOPOULOS G, KAKLAMANIS PG:Behçet's disease. Semin. Arthritis Rheum. (1998) 27 (4):197–217.
   PubMed Web of Science ®Google Scholar
• NAKAE K, MASAKI K, HASHIMOTO T, INABA G, MOCHIZUKI M, SAKANE T: Recent epidemiological features of Behcet's disease in Japan. In: Behçet's disease. Wechsler B, Godeau P (Eds.), Elsevier Science Publishers B.V., Amsterdam, Netherlands (1993):145–151.
   Google Scholar
• •This is the most dependable epidemiological study on Behçet's disease.
   Google Scholar
• ZOUBOULIS CC, KOTTER I, DJAWARI D et al.: Epidemiol-ogical features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med. J. (1997) 38 (6):411–422.
   PubMedGoogle Scholar
• MIZUKI N, INOKO H, OHNO S: Pathogenic gene respon-sible for the predisposition to Behçet's disease. Int. Rev. Immunol. (1997) 14(0:33–48.
   PubMedGoogle Scholar
• OHNO S, OHGUCHI M, HIROSE S, MATSUDA H, WAKISAKA A, AIZAWA M: Close association of HIA-Bw51 with Behçet's disease. Arch. Ophthalmol (1982) 100 (9) :1455–1458.
   PubMed Web of Science ®Google Scholar
• SAKANE T: New perspective on Behçet's disease. Int. Rev. Immunol. (1997) 14(0:89–96.
   PubMedGoogle Scholar
• ••This article summarises the pathological role of anti-heatshock protein autoimmune responses in the development of Behçet's disease.
   Google Scholar
• YAMASHITA N: Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Int. Rev. Immunol (1997) 14(0:11–19.
   PubMedGoogle Scholar
• TAKENO M, KARIYONE A, YAMASHITA N eta].: Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HIA-B51 transgenic mice. Arthritis Rheum. (1995) 38(3):426–433.
   Google Scholar
• ••This paper shows elegantly that HLA-B51 transgenic micehave neutrophil hyperfunction, suggesting the possible contribution of HLA-B51 to neutrophil abnormality in patients with Behçet's disease.
   Google Scholar
• SENSI A, GAVIOLI R, SPISANI S et al.: IBA B51 antigen associated with neutrophil hyperreactivity. Dis. Markers (1991) 9(6):327–331.
   PubMed Web of Science ®Google Scholar
• CHAJEK-SHAUL T, PISANTY S, KNOBLER H et al.: HIA-B51 may serve as an immunogenetic marker for a subgroup of patients with Behçet's syndrome. Am. J Med. (1987) 83(4):666–672.
   PubMed Web of Science ®Google Scholar
• •This paper is the first report with regard to the relation of HLA-B51 to neutrophil hyperfunction in Behçet's disease.
   Google Scholar
• LEHNER T: The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int. Rev. Immunol (1997) 14(0:21–32.
   PubMedGoogle Scholar
• ••This article reviews the pathological role of anti-heat shockprotein autoimmune responses in the development of Behçet's disease for the first time.
   Google Scholar
• EHRLICH GE: Vasculitis in Behçet's disease. Int. Rev. Immunol. (1997) 14(0:81–88.
   PubMedGoogle Scholar
• ••This article proposes that Behçet's disease is categorisedinto vasculitis syndromes.
   Google Scholar
• MIZUSHIMA Y: Behçet's disease. Curr. Opin. Rheumatol(1991) 3(0:32–35.
   PubMedGoogle Scholar
• YOSHIDA T, TANAKA M, SOTOMATSU A, OKAMOTO K,HIRAI S: Serum of Behçet's disease enhances superoxide production of normal neutrophils. Free Radic. Res. (1998) 28(1):39–44.
   PubMed Web of Science ®Google Scholar
• CARLETTO A, PACOR ML, BIASI D et al: Changes ofneutrophil migration without modification of in vitro metabolism and adhesion in Behçet's disease. J. Rheumatol. (1997) 24 (7):1332–1336.
   PubMed Web of Science ®Google Scholar
• TURAN B, GALLATI H, ERDI H, GURLER A, MICHEL BA,VILLIGER PM: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. (1997) 24(0:128–132.
   PubMedGoogle Scholar
• YOSIPOVITCH G, SHOHAT B, BSHARA J, WYSENBEEK A,WEINBERGER A: Elevated serum interleukin 1 receptors and interleukin 113 in patients with Behçet's disease: correlations with disease activity and severity. Isr. J. Med. Sci. (1995) 31(6):345–348.
   PubMedGoogle Scholar
• AL-DALAAN A, AL-SEDAIRY S, AL-BALAA S et al.:Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease. J Rheumatol. (1995) 22 (5):904–907.
   PubMed Web of Science ®Google Scholar
• TRIOLO G, ACCARDO-PALUMBO A, TRIOLO G, CARBONEMC, FERRANTE A, GIARDINA E: Enhancement of endothelial cell E-selection expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Olin. Immunol. (1999) 91 (3):330–337.
   Web of Science ®Google Scholar
• SAHIN S, AKOGLU T, DIRESKENELI H, SEN LS, LAWRENCE R: Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann. Rheum. Dis. (1996) 55(2):128–133.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI M, ITO M, NAKAGAWA A et al: Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology (2000) 36 (4):362–371.
   PubMed Web of Science ®Google Scholar
• YAMASHITA N, KANEOKA H, KANEKO S et al: Role of 78T lymphocytes in the development of Behçet's disease. Olin. Exp. Immunol (1997) 107 (2):241–247.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, SUZUKI N, TAKENO Metal: Fine antigen specificity of human 78 T cell lines (V79+) established by repetitive stimulation with a serotype (KTH-1) of a Gram-positive bacterium, Streptococcus sanguis. Eur. Immunol (1994) 24(7):1536–1543.
   PubMed Web of Science ®Google Scholar
• SAKANE T, SUZUKI N, UEDA Y et al.: Analysis of interleukin-2 activity in patients with Behçet's disease: ability of T cells to produce and respond to interleukin-2. Arthritis Rheum. (1986) 29 (3):371–378.
   PubMed Web of Science ®Google Scholar
• SUZUKI N, SAKANE T, UEDA Y, TSUNEMATSU T: Abnormal B cell function in patients with Behçet's disease. Arthritis Rheum. (1986) 29(2):212–219.
   PubMed Web of Science ®Google Scholar
• SAKANE T, KOTANI H, TAKADA S, TSUNEMATSU T: Functional aberration of T cell subsets in patients with Behçet's disease. Arthritis Rheum. (1 9 8 2) 25(10:1343-1351.
   Google Scholar
• PERVIN K, CHILDERSTONE A, SHINNICK T et al.: T cellepitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol. (1993) 151 (4):2273–2282.
   PubMed Web of Science ®Google Scholar
• ••This is the first report demonstrating that T-cells specific forheat shock protein 60-derived protein are involved in the development of Behçet's disease.
   Google Scholar
• KANEKO S, SUZUKI N, YAMASHITA N et al: Characteriza- tion of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Olin. Exp. Immunol. (1997) 108 (2):204–212.
   PubMed Web of Science ®Google Scholar
• ••This study shows that clonal expansion of T-cells specific forheat shock protein 60-derived protein is associated with exacerbations of Behçet's disease, especially in patients having uveitis and that the pathogenic T-cells preferentially produce Thl type cytokines.
   Google Scholar
• DIRESKENELI H, HASAN A, SHINNICK T et al.: Recogni-tion of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Scand. j Immunol. (1996) 43(4):464–471.
   PubMed Web of Science ®Google Scholar
• SUGI-IKAI N, NAKAZAWA M, NAKAMURA S, OHNO S, MINAMI M: Increased frequencies of interleukin-2- and interferon-7-producing T cells in patients with active Behçet's disease. Invest. Ophthalmol. Vis. Sci. (1998) 39(6):996–1004.
   PubMed Web of Science ®Google Scholar
• FRASSANITO MA, DAMMACCO R, CAFFORIO P, DAMMACCO F: Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. (1999) 42 (9):1967–1974.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL STUDY GROUP FOR BEKET'S DISEASE. Criteria for diagnosis of Behçet's disease. Lancet (1990) 335 (8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• ••The simple diagnostic criteria with high specificity andsensitivity enable us to conduct international comparative studies of patients with Behçet's disease.
   Google Scholar
• SAKANE T, TAKENO M, SUSUKI N: Behçet's disease. N Engl. J. Med. (2000) 342(8):588–589.
   Google Scholar
• BANG D, HUR W, LEE ES, LEE S: Prognosis and clinical relevance of recurrent oral ulceration in Behçet's disease. J. Dermatol (1995) 22 (12):926–929.
   PubMedGoogle Scholar
• NUSSENBLATT RB: Uveitis in Behçet's disease. Int. Rev. Immunol. (1997) 14(0:67–79.
   PubMedGoogle Scholar
• BENAMOUR S, ZEROUAL B, ALAOUI FZ: Joint manifesta-tions in Behcet's disease: a review of 340 cases. Rev. Rhum. Engl. Ed.(1998) 65(5):299–307.
   PubMedGoogle Scholar
• SERDAROGLU P: Behçet's disease and the nervous system. J. Neurol. (1998) 245 (4):197–205.
   PubMed Web of Science ®Google Scholar
• AKMAN-DEMIR G, SERDAROGLU P, TASCI B: Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain (1999) 122(10:2171–2182.
   Google Scholar
• KIDD D, STEUER A, DENMAN AM, RUDGE P: Neurological complications in Behçet's syndrome. Brain (1999) 12 2 (10:2183–2194.
   Google Scholar
• HATZINIKOLAOU P, VAIOPOULOS G, MAVROPOULOS S,AVDELIDIS D, STAMATELOS G, KAKLAMANIS P: Adaman-tiadis-Behçet's syndrome: central nervous system involvement. Acta. Neurol. Scand. (1993) 87(4):290–293.
   PubMedGoogle Scholar
• HAMURYUDAN V, YURDAKUL S, MORAL F et al.: Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br]. Rheumatol (1994) 33 (1):48–51.
   PubMedGoogle Scholar
• TERADA Y, TAKAMOTO T, NAKAMURA T et al: Behçet's disease associated with aortic and mitral regurgita-tion:report of two cases. J Cardiol (1988) 18 (3):857–865.
   PubMedGoogle Scholar
• SIEPMANN M, KIRCH W: Coronary anomaly in Behçet's syndrome. Rheumatol. Int. (1997) 17(0:39–42.
   PubMedGoogle Scholar
• TUNACI A, BERKMEN YM, GOKMEN E: Thoracic involve-ment in Behçet's disease: pathologic, clinical and imaging feature. Am. J. Roentgenol (1995) 164(1):51–56.
   PubMed Web of Science ®Google Scholar
• BASOGLU T, CANBAZ F, BERNAY I, DANACI M: Bilateral pulmonary artery aneurysms in a patient with Behçet's syndrome: evaluation with radionuclideangi-ography and WQ lung scanning. Clin. Nucl. Med. (1998) 23(10:735–738.
   PubMedGoogle Scholar
• MIZUSHIMA Y, MATSUMURA N, MORI M eta].: Colchicine in Behçet's disease. Lancet (1977) 2(8046):1037.
   Google Scholar
• •This is the first report describing the clinical efficacy of colchicine, which is one of the most widely used drugs in the treatment of Behçet's disease.
   Google Scholar
• AKTULGA E, ALTAC M, MUFTUOGLU A et al: A double blind study of colchicine in Behçet's disease. Haemato-logica (1980) 65(3):399–402.
   PubMed Web of Science ®Google Scholar
• MIYACHI Y, TANIGUCHI S, OZAKI M, HORIO T. Colchi-eine in the treatment of the cutaneous manifestations of Behçet's disease. Br]. Dermatol (1981) 104 (1):67–69.
   PubMed Web of Science ®Google Scholar
• TERKELTAUB RA: Pathogenesis and treatment of crystal-induced inflammation. In: Arthritis and Allied Conditions: a Textbook of R (13th Edition). Koopman WJ (Ed.), Williams & Wilkins, Baltimore, USA (1997):3085–4102.
   Google Scholar
• MATSUMURA N, MIZUSHIMA Y: leucocyte movement and colchicine treatment in Behçet's disease. Lancet (1975) 2(7939):813.
   PubMed Web of Science ®Google Scholar
• HAMURYUDAN V, MAT C, SAIP S et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128 (6):443–450.
   PubMed Web of Science ®Google Scholar
• •This study shows the clinical efficacy of thalidomide for male patients with Behçet's disease.
   Google Scholar
• HAMZA M, HAMZAOUI K, AYED K: Treatment of Behçet's disease with dapsone. Clin. Rheumatol. (1989) 8(1):113–114.
   PubMed Web of Science ®Google Scholar
• YASUI K, OHTA K, KOBAYASHI M, AIZAWA T, KOMIYAMA A: Successful treatment of Behçet disease with pentoxifylline. Ann. Intern. Med. (1996) 124 (10):891–893.
   PubMed Web of Science ®Google Scholar
• •This study provides evidence that pentoxifylline is effective for Behçet's disease via inhibition of TNF-a production.
   Google Scholar
• HAMURYUDAN V, OZYAZGAN Y, HIZLI N eta].: Azathio-prine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. (1997) 40 (4):769–774.
   Google Scholar
• YAZICI H, PAZARLI H, BARNES CG et al: A controlled trial of azathioprine in Behçet's syndrome. N Engl. J. Med. (1990) 322(5):281–285.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrates the usefulness of cytotoxicimmunosuppressants in the treatment of Behçet's disease.
   Google Scholar
• TESSLER HH, JENNINGS T: High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br. J. Ophthalmol. (1990) 74 (6):353–357.
   PubMed Web of Science ®Google Scholar
• DAVATCHI F, BAYGAN F, CHAMS H, CHAMS C: Cyclophosphamide in the treatment of the ocular manifestations of Behçet's disease. J Rheumatol (1984) 11 (3):404–405.
   PubMed Web of Science ®Google Scholar
• KOTTER I, DURK H, SAAL J, FIERLBECK G, PLEYER U, ZIEHUT M: Therapy of Behçet's disease. Ger. J. Ophthalmol (1996) 5(2)92–97.
   Google Scholar
• MASUDA K, NAKAJIMA A, URAYAMA A, NAKAE K, KOGURE M, INABA G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet (1989) 1 (8647):1093–1096.
   PubMed Web of Science ®Google Scholar
• ••This study shows the clinical efficacy of cyclosporin forBehçet's disease and contributes to propagation of the cyclosporin therapy, which is still the most effective strategy for uveitis in patients with Behçet's disease.
   Google Scholar
• RAO A, LUO C, HOGAN PG: Transcription factors of the NFAT family: regulation and function. Ann. Rev. Immunol (1997)15:707–747.
   PubMed Web of Science ®Google Scholar
• OZYAZGAN Y, YURDAKUL S, YAZICI H et al.: Low dosecyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br. J. Ophthalmol (1992) 76(4):241–243.
   PubMed Web of Science ®Google Scholar
• SUZUKI N, KANEKO S, ICHINO M, MIHARA S, WAKISAKAS, SAKANE T: In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. Arthritis Rheum. (1997) 40 (6):1157–1167.
   PubMed Web of Science ®Google Scholar
• KOTAKE S, HIGASHI K, YOSHIKAWA K, SASAMOTO Y,OKAMOTO T, MATSUDA H: Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology (1999) 106 (3):586–589.
   PubMed Web of Science ®Google Scholar
• •This study shows that the neurotoxicity is the most important limiting factor in the treatment of Behçet's disease with cyclosporin.
   Google Scholar
• LEE KS, KIM SJ, LEE BC, YOON DS, LEE WJ, CHI HS: Surgical treatment of intestinal Behçet disease. Yonsei Med. J. (1997) 38(6):455–460.
   PubMedGoogle Scholar
• HIROHATA S, SUDA H, HASHIMOTO T: Low-dose weekly methotrex ate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol. Sci. (1998) 159(2):181–185.
   PubMed Web of Science ®Google Scholar
• O'DUFFY JD, CALAMIA K, COHEN S et al.: Interferon-alpha treatment of Behçet's disease. J Rheumatol. (1998) 25(10):1938–1944.
   Google Scholar
• ZOUBOULIS CC, ORFANOS CE: Treatment of Adam an tia-des-Behçet disease with systemic interferon a. Arch. Dermatol (1998) 134(8):1010–1016.
   PubMed Web of Science ®Google Scholar
• •This article reviews the clinical data from 144 Behçet's disease patients treated with IFN-a in 22 reported clinical trials from all over the world.
   Google Scholar
• KOTTER I, ECKSTEIN AK, STUBIGER N, ZIERHUT M: Treatment of ocular symptoms of Behçet's disease with interferon 0C2a: a pilot study. Br. J. Ophthalmol (1998) 82(5):488–494.
   PubMed Web of Science ®Google Scholar
• DEMIROGLU H, OZCEBE OI, BARISTA I, DUNDAR S, ELDEM B: Interferon a-2b, colchicine and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial. Lancet (2000) 355 (9204):605–609.
   PubMed Web of Science ®Google Scholar
• ••This article first demonstrates the efficacy of UFN-a-2b in adouble-blind randomised study. The study also emphasises that the earlier introduction of IFN-a2b leads to the better long-term prognosis.
   Google Scholar
• TSAMBAOS D, EICHELBERG D, GOOS M: Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch. Dermatol. Res. (1986) 278 (4):335–336.
   PubMed Web of Science ®Google Scholar
• HAMZA M, SLIM A: Herpes simplex virus antigens in sera of patients with Behçet's disease. Clin. Rheumatol (1991) 10(4):456.
   PubMed Web of Science ®Google Scholar
• DAVIS GL: Interferon treatment of chronic hepatitis C. Am. J. Med. (1994) 96 (1A):41S–465.
   Google Scholar
• KANEKO F, TAKAHASHI Y, MURAMATSU R et al.: Natural killer cell numbers and function in peripheral lymphoid cells in Behçet's disease. Br. J Dermatol. (1985) 113(3):313–318.
   PubMed Web of Science ®Google Scholar
• CALABRESE L, FLEISCHER AB: Thalidomide: current and potential clinical applications. Am. J Med. (2000) 108 (6):487–495.
   PubMed Web of Science ®Google Scholar
• •This article reviews the clinical application of thalidomide.
   Google Scholar
• MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immunol. Today (1999) 20(12):538–540.
   PubMedGoogle Scholar
• •This article briefly reviews the anti-inflammatory pharma-cological effects of thalidomide.
   Google Scholar
• HAMZA MH: Treatment of Behcet's disease withthalidomide. Clin. Rheumatol (1986) 5 (3):365–371.
   PubMed Web of Science ®Google Scholar
• JORIZZO JL, SCHMALSTIEG FC, SOLOMON AR, JR. et al:Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch. Intern. Med. (1986) 146 (5):878–881.
   PubMed Web of Science ®Google Scholar
• LA MAESTRA L, ZANINONI A, MARRIOTT JB, LAZZARIN A,DALGLEISH AG, BARCELLINI W: The thalidomide analogue CC-3052 inhibits HIV-1 and tumor necrosis factor-alpha (TNF-a) expression in acutely and chroni-cally infected cells in vitro. Clin. Exp. Immunol (2000) 119 (1):123–129.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, FREEMAN SL, CORRAL LG, OCAMPO CJ,KAPLAN G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin. Exp. Immunol (1999) 118(2):315–321.
   PubMed Web of Science ®Google Scholar
• KLARESKOG L, MCDEVITT H: Rheumatoid arthritis and its animal models: the role of TNF-OC and the possible absence of specific immune reactions. Curr. Opin. Immunol. (1999) 11 (6):657–662.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS KA, TARGAN SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. (2000) 51:289–298
   PubMed Web of Science ®Google Scholar